Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Variable Rate Preferred Invesco ETF (VRP)

Variable Rate Preferred Invesco ETF (VRP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Invesco
  • Assets Under Management 1,721,481,200
  • Shares Outstanding, K 72,100
  • 60-Month Beta 0.44
Trade VRP with:
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 1.48 (6.19%)
  • Most Recent Dividend 0.109 on 06/24/24
  • Management Fee 0.50%
  • Sectors:

    ETFs - Mixed Asset

Options Overview Details

View History
  • Implied Volatility 18.44% ( +18.44%)
  • Historical Volatility 5.27%
  • IV Percentile 83%
  • IV Rank 100.00%
  • IV High 18.44% on 06/24/24
  • IV Low 13.25% on 11/29/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 1
  • Put/Call OI Ratio 999.99
  • Today's Open Interest 10
  • Open Int (30-Day) 10

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.64 +1.06%
on 05/30/24
24.08 -0.79%
on 06/21/24
-0.01 (-0.04%)
since 05/24/24
3-Month
23.40 +2.09%
on 04/17/24
24.08 -0.79%
on 06/21/24
+0.07 (+0.29%)
since 03/25/24
52-Week
21.60 +10.60%
on 10/27/23
24.08 -0.79%
on 06/21/24
+1.80 (+8.15%)
since 06/23/23

Most Recent Stories

More News
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

Initiated ENHANCE Phase 3 clinical trials in COPD

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Posters highlight ensifentrine’s potential to provide rapid benefits

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020

New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD

Results expected in the first half of 2021

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

Completed $200 million private placement post period

VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma Announces August 2020 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...

LSE.LN : 8,620.000 (-0.58%)
VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)
Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update

LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...

LSE.LN : 8,620.000 (-0.58%)
VRP : 23.88 (-0.25%)
VRNA : 15.00 (-4.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Invesco Variable Rate Preferred ETF is based on the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The Fund will generally invest at least 90% of its total assets in preferred securities that comprise the Index. The Index is a market capitalization-weighted index designed...

See More

Top 10 Holdings

Name % Holdings
Invesco Government & Agency Portfolio Institutio 2.08%
Wells Fargo & Co 1.52%
JPMorgan Chase & Co 1.36%
N/A 1.21%
JPMorgan Chase & Co 1.17%
Charles Schwab Corp/The 1.10%
BP Capital Markets PLC 1.09%
Goldman Sachs Group Inc/The 1.05%
Bank of America Corp 1.03%
JPMorgan Chase & Co 1.03%

See More

Key Turning Points

3rd Resistance Point 24.02
2nd Resistance Point 24.01
1st Resistance Point 23.97
Last Price 23.88
1st Support Level 23.92
2nd Support Level 23.91
3rd Support Level 23.87

See More

52-Week High 24.08
Last Price 23.88
Fibonacci 61.8% 23.13
Fibonacci 50% 22.84
Fibonacci 38.2% 22.55
52-Week Low 21.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar